Sano Women's Health is focused on developing safer and more effective treatments for infections that affect the quality of life for millions of women. Vaginal yeast infections are becoming more difficult to effectively treat given the rise in resistance to current antifungal treatments. For the past several decades, bacteria and fungi have been acquiring resistance to current drugs, requiring the development of new drugs to stay ahead of the evolutionary curve.
Our Pipeline
Occidiofungin The Fungus Killer
Occidiofungin is under investigation as a response to increasing prevalence of antifungal resistance. Its unique mechanism of action suggests great potential in the fight against drug resistant fungi. FDA has approved an investigational new drug application (INDA) allowing Phase 1 clinical trials.
